top of page
gradientForSurfBreak.png

Item List

Dec 20, 2022
Newswires
xCures partners with RenovoRx to assist patients in accessing RenovoRx’s TIGeR-PaC study

xCures, Inc. is proud to announce their partnership with RenovoRx, a clinical-stage biopharmaceutical company that focuses on fighting cancer through localized treatment of difficult-to-treat tumors, such as pancreatic adenocarcinoma. Through this collaboration, xCures will help eligible pancreatic cancer patients access a Phase III clinical study entitled, Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine plus Nab-Paclitaxel following Induction with sequential IV Gemcitabine plus Nab-Paclitaxel and Radiotherapy for Unresectable Locally Advanced Pancreatic Cancer (TIGeR-PaC).

Recent Posts

Portfolio Company

Carlsmed.png

Carlsmed Q2 Earnings Call Highlights
...

Yahoo Finance

Aug 5, 2026

Portfolio Company

Carlsmed.png

Epitel Secures $26 Million Series B to Expand Remote Wireless EEG Monitoring
...

Yahoo Finance

Jul 28, 2026

Portfolio Company

Carlsmed.png

Tombot Closes $7 Million Series A3 Growth Financing to Scale Operations and Expa ...

Businesswire

Jun 25, 2026

surf break copy_edited_edited.jpg
surbreak-19.png
WM360_logo-18.png
bottom of page